CollPlant Biotechnologies Ltd. Sponsored ADR

CLGN Healthcare Biotechnology

CollPlant Biotechnologies Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, up 360.4% from fiscal 2024. In the quarter to June 2026, revenue fell 39.7%, EPS grew 32.5% and free cash flow grew 5.08%, each against the same quarter a year earlier.

3.63 0.05 −1.36%
Market cap
$7.0M
P/E
0.0×
Fwd P/E
−0.7×
Dividend yield
—
F-score
4/9
Altman Z
−16.87
Beneish M
−3.20
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 4 2 2
ROE
(92.74%) (117.56%) (151.99%) (161.98%)
ROA
(66.57%) (77.90%) (99.53%) (101.59%)
ROIC
(1,612.55%) (5,478.53%) (3,125.00%) 0.00%
Return on Tangible Assets
(140.76%) (207.46%) (300.55%) (509.49%)
Average Days of Receivables
37.46 34.48 218.62 464.86
Free Cash Flow per Share
(7.87) (7.74) (8.24) (7.76)
Free Cash Flow
(10.02) (9.45) (11.33) (11.20)
Capital Expenditures
(0.07) (0.03) (0.02) (0.01)
Other line items
Cash ROIC
(55.25%) (78.51%) (119.06%) (189.99%)
Accounts Receivable Turnover
7.23 5.88 1.16 0.83
Accounts Payable Turnover
1.12 1.13 1.37 3.24
Inventory Turnover
1.84 1.65 1.42 2.45
Average Days of Payables
246.52 266.65 240.68 69.68
Days of Inventory on Hand
215.41 250.47 257.36 146.98
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
353.54% 345.30% 1,994.86% 2,173.58%
Selling, General and Administrative Expense of Revenue
206.75% 203.80% 1,186.63% 1,405.66%
Share Based Compensation of Revenue
58.22% 42.13% 204.88% 191.51%
Interest Coverage
— — — (30.26)
Operating CF/Net income
0.82 0.82 0.86 0.89
Depreciation/Fixed assets
0.57 0.62 0.69 0.81
Capex/Depreciation
(0.07) (0.03) (0.03) (0.01)
Revenue per Share
1.95 1.94 0.28 0.22
Operating CF per Share
(7.82) (7.72) (8.22) (7.76)
Capex per Share
(0.05) (0.02) (0.02) (0.01)
Capex to Sales
0.03 0.01 0.06 0.03

Fold the line items

Columns are period end dates · fundamentals updated 6 Oct 2026